JHS Svendgaard Laboratories Ltd
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of
oral and dental products for national and international brands[1]
- Market Cap ₹ 201 Cr.
- Current Price ₹ 23.5
- High / Low ₹ 39.5 / 15.5
- Stock P/E
- Book Value ₹ 21.2
- Dividend Yield 0.00 %
- ROCE -1.69 %
- ROE -2.36 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.11 times its book value
- Company's working capital requirements have reduced from 112 days to 71.8 days
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.17%
- The company has delivered a poor sales growth of -10.6% over past five years.
- Promoter holding is low: 34.6%
- Company has a low return on equity of -1.22% over last 3 years.
- Earnings include an other income of Rs.4.89 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Personal Care - Indian
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
60 | 35 | 55 | 100 | 104 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 80 | |
48 | 39 | 59 | 93 | 92 | 126 | 124 | 137 | 99 | 87 | 94 | 72 | 78 | |
Operating Profit | 12 | -4 | -4 | 7 | 12 | 14 | 0 | 2 | 2 | -1 | -9 | -1 | 2 |
OPM % | 20% | -11% | -7% | 7% | 11% | 10% | 0% | 1% | 2% | -1% | -11% | -1% | 2% |
12 | -3 | -6 | -17 | 0 | 32 | 6 | 3 | 7 | 9 | -7 | 4 | 5 | |
Interest | 10 | 14 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 0 |
Depreciation | 14 | 15 | 12 | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 7 |
Profit before tax | 0 | -35 | -22 | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -1 |
Tax % | 1,357% | -18% | 0% | 0% | -327% | 32% | -19% | -17% | -39% | 4,000% | -24% | 18% | |
-4 | -29 | -22 | -22 | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -12 | |
EPS in Rs | -1.56 | -11.95 | -9.20 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | 1.97 | -1.39 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | -11% |
3 Years: | -11% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 6% |
5 Years: | % |
3 Years: | % |
TTM: | -735% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 10% |
3 Years: | 1% |
1 Year: | -12% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | -1% |
Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 24 | 24 | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 |
Reserves | 65 | 38 | 96 | 63 | 90 | 113 | 116 | 117 | 124 | 121 | 95 | 91 | 96 |
101 | 54 | 19 | 3 | 2 | 2 | 7 | 9 | 7 | 6 | 3 | 5 | 4 | |
41 | 74 | 33 | 19 | 19 | 32 | 39 | 55 | 33 | 30 | 52 | 22 | 22 | |
Total Liabilities | 232 | 190 | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 208 |
135 | 121 | 108 | 65 | 65 | 71 | 71 | 66 | 63 | 59 | 65 | 90 | 90 | |
CWIP | 0 | 0 | 0 | 1 | 1 | 1 | 5 | 7 | 9 | 20 | 9 | 1 | 2 |
Investments | 0 | 0 | 0 | 0 | 1 | 18 | 10 | 6 | 2 | 4 | 3 | 3 | 4 |
97 | 70 | 63 | 57 | 89 | 118 | 137 | 163 | 154 | 140 | 152 | 102 | 112 | |
Total Assets | 232 | 190 | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 208 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
60 | 28 | 7 | -4 | -4 | 14 | -11 | 10 | 12 | -9 | 23 | -9 | |
-22 | 3 | 1 | 1 | -3 | -27 | -7 | -11 | -2 | -5 | 10 | -22 | |
-39 | -29 | -10 | 4 | 10 | 14 | 13 | 0 | 10 | -2 | -1 | 2 | |
Net Cash Flow | -2 | 2 | -1 | 2 | 3 | 0 | -5 | -0 | 20 | -16 | 32 | -28 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 220 | 188 | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 |
Inventory Days | 132 | 122 | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 177 |
Days Payable | 407 | 95 | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 |
Cash Conversion Cycle | -55 | 215 | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 |
Working Capital Days | 29 | -368 | 84 | 59 | 56 | 122 | 187 | 202 | 277 | 222 | 43 | 72 |
ROCE % | 1% | -10% | -12% | -3% | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Of Newspaper Publication of Un-audited Financial Results for the quarter and half year ended September 30, 2024.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
13 Nov - Appointment of Mr. Paramvir Singh Pabla as Additional Director.
-
JHS Has informed About Statement Of Deviation(S) Or Variation(S) Under Reg. 32 For The Quarter Ended September 30, 2024.
13 Nov - Statement of deviation in fund utilization for Q3 2024.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
13 Nov - Appointment of M/s V.K. Khosla & Co. as statutory auditor.
-
Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
13 Nov - Resignation of Lodha & Co as statutory auditor.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
Business Overview:[1]
JHSSLL manufactures Toothbrushes, Toothpastes, Mouthwash and Denture Tablets. Apart from working on its own brands viz. Dr. Gold, Aquawhite, etc. company also offers Contract Manufacturing Partnership to brands in domestic and international markets